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CancerThe encapsulation of cytotoxic drugs within liposomes enhances pharmacokinetics and allows passive accumu-
lation within tumors. However, liposomes designed to achieve good stability during the delivery phase often
have compromised activity at the target site. This problem of inefﬁcient and unpredictable drug release is
compounded by the present lack of low-cost, non-invasive methods to measure such release. Here we show
that focused ultrasound, used at pressures similar to those applied during diagnostic ultrasound scanning, can
be utilised to both trigger and monitor release of payload from liposomes. Notably, drug release was inﬂuenced
by liposome composition and the presence of SonoVue®microbubbles, which provided the nuclei for the initia-
tion of an event known as inertial cavitation. In vitro studies demonstrated that liposomes formulatedwith a high
proportion of 1,2 distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) released up to 30% of payload following
ultrasound exposure in the presence of SonoVue®, provided that the exposure created sufﬁcient inertial cavita-
tion events, as characterised by violent bubble collapse and the generation of broadband acoustic emissions. In
contrast a ‘Doxil’-like liposome formulation gave no such triggered release. In pre-clinical studies, ultrasound
was used as a non-invasive, targeted stimulus to trigger a 16-fold increase in the level of payload release within
tumors following intravenous delivery. The inertial cavitation events driving this release could be measured
remotely in real-time and were a reliable predictor of drug release.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
The powerful cytotoxicity of lowmolecular weight chemotherapeu-
tics could provide far greater anticancer efﬁcacy if dosing was not re-
stricted by severe adverse effects in non-target tissues. In response,
blood stable liposomal delivery systems have been developed to extend
the circulation of these drugs and to allow their selective passive
accumulation into tumors via the enhanced permeability and retention
effect (EPR) [1]. However, although formulations such as Doxil®, an
HSPC-based liposome containing doxorubicin, have provided clinical
beneﬁt in the treatment of cancers such as Kaposi's sarcoma [2,3], the
more widespread use of such agents has been restricted. In particular,
their clinical efﬁcacy is limited by two main factors: poor penetration
into non-vascularised tumor regions and poor release of payloadwithin
the tumor [4,5].
Although it is clear that the EPR effect increases accumulation of
liposomes in the tumor, this accumulation is predominantly arounde).
pen access under CC BY-NC-ND licensthe perivascular space, usually in the periphery of the tumor [4,6]. To
achieve effective treatment of the whole tumor such limited pene-
tration needs to be overcome. Furthermore, depending on the
formulation used, the release of free drug may only occur over ex-
tended periods, and so the required therapeutic concentration and
distribution of free drug may never be achieved [5]. It is therefore
apparent that although the stability provided by liposomal
formulations is desirable during the intravenous delivery phase, fol-
lowing arrival within the tumor, drug in its free form is required to
provide higher and more widespread bio-availability. In response,
several strategies have been developed to instigate the tumor-
speciﬁc release of payload from liposomes. These have included al-
terations to liposome formulation to achieve sensitivity to the
phenotypically distinct tumor environment [7,8] or to externally
applied stimuli such as heat or ultrasound [9–13].
Ultrasound (US) can initiate the release of drugs from liposomes via
an event called inertial cavitation,whereby the rarefactional phase of an
ultrasound wave causes the expansion of a gas bubble followed by a vi-
olent collapse due to the inertia of the surroundingmedia. This collapse
creates shock waves which can disrupt the stability of co-localised lipo-
somal drug carriers. To date, studies have concentrated on the use ofe. 
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most recently such parameters have been used to achieve a variable
level of triggered drug release following an intratumoral injection of li-
posomes [14]. However, concerns persist over the damage to non-target
tissue that such US exposure parameters may cause and whether ulti-
mately they will be widely clinically applicable. An alternative strategy
is to utilise high-frequency US pulses at pressures in the diagnostic
range in the presence of pre-existing gas bubbles. This provides an iner-
tial cavitation stimulus for drug release using safe, clinically achievable
US exposure conditions and approved US contrast agents [15]. Indeed,
in the context of improving the delivery of therapeutics such as
oncolytic viruses, this approach has already shown great promise [16].
A further advantage of this approach is that US-induced cavitation
events produce distinct acoustic emissions that can be recorded and
characterised providing non-invasive feedback, a feature which has
proven useful in ablative US applications [17–19].
Here we demonstrate that liposomes can be formulated to achieve
sensitivity to cavitation events created by the application of focused
US in the presence of a gas ﬁlled microbubble formulation SonoVue®
(SV). We show that such cavitation events can be triggered using US
parameters similar to those used in diagnostic US scanning and can be
recorded in real time. These studies may ultimately provide new
methods by which the efﬁcacy and monitoring of intravenous drug
delivery to tumors can be improved in the clinical setting.
2. Materials and methods
2.1. Chemicals and cells
Hydrogenated soyphosphocholine (HSPC, 840058), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine (DSPE, 850715) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (DSPE-PEG 880120) were purchased from Avanti Polar Lipids
Inc (Ala, USA). Cholesterol (C8667) was purchased from Sigma (UK).
D-Luciferin potassium salt was purchased from Gold Biotechnology,
MO, USA, and luciferase from Photinus pyralis (ﬁreﬂy) was from Sigma
(L9506). B16-F10-luciferase cells were purchased from Caliper life
sciences (USA) and maintained as recommended by the manufacturer.
2.2. Liposome formulation
Liposomes were formulated by mixing HSPC, cholesterol and DSPE-
PEG at ratios of 56:39:5 (HSPC liposomes) or DSPE, cholesterol, DSPC
and DSPE-PEG at ratios of 65:25:3:7 (DSPE liposomes) in 2 chloroform:
1 methanol, in a round bottomed ﬂask. To confer triggered
destabilisation upon liposomes, the lipid DSPE was incorporated. This
lipid has a packing parameter above 1 and a propensity to form inverted
hexagonal structures at pH b9 when the head phosphate group and
amine group carry opposing charges. A 3% DSPC was included to
enhance stability. After complete dissolution, rotary evaporation for
30 min at 55 °C achieved a thin ﬁlm,which after drying under high vac-
uum overnight was rehydrated in 300 mM Tris pH 10 for 60 min.
Subsequent puriﬁcation, sizing and achievement and assessment of lu-
ciferin loadingwas performed as described by Carlisle et al. [20], except
that a multiwell plate reader (BMG, Fluorstar Optima) was used. Size
and polydispersity were measured using a Zetasizer Nano ZS (laser
wavelength 633 nm; Malvern Instruments, UK). The general purpose
analysis mode; 3 runs per measurement; and backscatter angle of 173
degrees were used.
2.3. Stability and blood component interactions
Liposomes were mixed with freshly isolated, complement active
human plasma for 5, 10, 15, 20, 25 or 30 min at 37 °C and the release
of payload measured. Sample was heated to 100 °C or not and then
assayed for free luciferin as described by Carlisle et al. [20]. The amountof free or still encapsulated luciferin could then be calculated as a
percentage of the total.
Stability in vivowas tested using a luciferase reporter mouse system
developed from that previously described [21]. HDLacOLuc transgenic
mice were generated by isolating the transgenic construct from
pHDLacOluc via BglII/BamHI digestion followed by PvuI digestion to
leave a 2.7-kb isolated fragment, which was puriﬁed and diluted to
5 ng/μl in microinjection buffer (10 mM Tris–HCl pH 7.4, 0.1 mM
EDTA). Three-week-old female B6CBAF1 mice were superovulated and
mated. The resulting fertilised oocytes were collected from the oviduct
of plugged female mice and cultured until two clear pronuclei were vis-
ible. The puriﬁed HDLacOLuc transgenic constructs were microinjected
into one of the pronuclei and injected embryos were cultivated over-
night to the two-cell stage. Two-cell embryos were then re-implanted
into the oviduct of pseudo pregnant CD1 foster mothers at 0.5 days
post-corium. Between 18 and 19 days later, pups were born from the
fostermothers. Ear biopsies from these pupswere taken, DNA extracted
and PCR performed to identify transgenic founder mice. Founder mice
were mated with C57Bl/6 mice and the resultant pups genotyped to
identify transgenics. These F1 transgenics were mated with C57Bl/6
mice to produce an F2 generation and establish the line [22]. An intrave-
nous injection of 50 μg of free luciferin and imaging 30 min post-
injection using an IVIS 100 system (Caliper Life Sciences, USA) con-
ﬁrmed the ubiquitous expression of the luciferase reporter gene
throughout the mice. HSPC or DSPE liposomes encapsulating the same
50 μg quantity of luciferin were then injected intravenously and lumi-
nescence measured after 30 min. Images were all identically scaled
(lower limit 1 × 105, upper limit 1 × 108 photons/second/cm2).
2.4. Ultrasound generation and cavitation detection
A 0.5-MHz spherically focused, single-element ultrasound transduc-
er (H-107D SN13; Sonic Concepts, Bothell, Washington, USA) was used
as the driving transducer to insonate samples (setup shown in supple-
mentary Fig. 1). The elliptical focal zone at −6 dB measured (4 mm
laterally × 37 mm axially). Custom-made software using LabView 8.5
(National Instruments) was used to control and collect ultrasound sig-
nals. Voltage pulses from a function generator (33250A; Agilent Tech-
nologies, Santa Clara, CA, USA) were ampliﬁed using a 55-dB, RF
power ampliﬁer (A300 Power Ampliﬁer, 017098, Electronics and Inno-
vation; Rochester, NY, USA) and passed through its matching network
to the driving transducer. An absolute pressure calibration and beam
proﬁle characterisationwas performedusing a 0.4-mmdiameter needle
hydrophone (ONDA 1056; Onda Corporation, Sunnyvale, CA, USA). All
pressures reported throughout the present study are peak rarefactional
focal pressures (PRFPs). Acoustic emissions were detected passively
using a 7.5-MHz single-element focused transducer (SN 671678,
Panametrics, Waltham, MA, USA) referred to as the passive cavitation
detector (PCD). The PCD was inserted through a central opening in
the driving transducer and was confocally and coaxially aligned with
the driving transducer as in [23]. Voltage signals were ﬁltered using a
2-MHz analogue high pass ﬁlter (FILT-HP2-A; Allen Avionics Inc., NY,
USA) to exclude reﬂections of the driving frequency, ampliﬁed by a fac-
tor of 5 (SR445A; Stanford Research Systems, Sunnyvale, CA, USA) and
then acquired using a DAQ card and saved on a computer.
2.5. In vitro experiments
ADelrin® cylindrical phantom (volume = 6.3 ml)with acoustically
transparent Mylar® sheets on the front and back face was used to hold
each sample. Liposomal samples (50 μl) were diluted in PBS and mixed
with or without SV (300 μl) in the phantom. A 3D positioning system
was used to immerse the phantom in the water tank, aligned with the
transducer focus. A magnetic PTFE stir bar with a stir plate (Variomag
Compact, Thermo Electron Corporation) was used to mix samples for
15 s, 1 min before ultrasound exposure. Samples were insonated at
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Fig. 1. Assessment of size and stability of liposomes to temperature and plasma. The hy-
drodynamic diameter and polydispersity of liposomes were measured as described in
methods, n = 3, ±standard deviation. For stability studies, liposomes were incubated
with neat human plasma and luciferin release assayed and plotted as percentage of total
dose. N =3, standard deviation shown. In vivo stability was assessed using a reporter
mouse model with body-wide endogenous expression of luciferase (see methods). Free
luciferin, HSPC liposomes or DSPE liposomes (all 50 μg luciferin) were injected intrave-
nously and luminescence analysed at 30 min.
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shown in supplementary Table 1. A pulse length of 100 ms and pulse
repetition period of 2 s (i.e., 5% duty cycle) was used to insonate each
sample for 30 s. Data post processing was carried out using custom-
designed software in Matlab® (MathWorks). A fast Fourier transform
(FFT) was conducted, and all data were displayed as power spectral
densities. Electrical energy was calculated as the integral across all fre-
quencies between 0 and 15 MHz and across time points over 30 s for
each power spectral density. The inﬂuence of ultrasound exposure on
temperature increase was assessed by placing a thermocouple (Type
T, Omega Thermocouple) connected to a thermocouple reader (TC-08,
Pico Technology Ltd) within the phantom during exposure.
2.6. In vivo experiments
C57BL6micewere implantedwith B16-F10-luciferase tumors as de-
scribed by Carlisle et al. [20], and the ultrasound system and exposure
conditions were as described by Bazan-Peregrino et al. [24], except
that total exposure time was 12 min, with 25 μL of SV injected every
90 s and repositioning of the focal volume every 3 min. A total of
100 μL of liposome sample (158 μg luciferin) was injected. Imaging
was performed using an IVIS 100 system 100 (Caliper Life Sciences,
USA). Ultrasound exposure was performed immediately after injection,
i.e., when bloodstream concentrations of liposomes and SVwas highest,
to ensure the best chance of co-localisation of these two agents within
tumor vasculature. In vitro assay of liver, tumor and blood luciferin
content was performed as described by Carlisle et al. [20]. Energy from
cavitation events were represented as normalised variance as described
by Bazan-Peregrino et al. [24].
3. Results
3.1. Loading and in vitro and in vivo stability of DSPE or HSPC liposomes
Dynamic light scattering conﬁrmed the formation of stable lipo-
somes of similar size (diameter less than 150 nm) and polydispersity
(PDI approximately 0.1) to liposomes produced using HSPC (Fig. 1A).
Although this diameter is greater than that of formulations currently
used in the clinics, this size was chosen to exceed the cutoff for the en-
dothelial fenestrae ofmurinehepatocytes and therebyprovidemore ex-
tended circulation in our pre-clinical studies [25]. Stability experiments
veriﬁed that the inclusion of DSPEwithin the liposomes did not increase
their payload release upon exposure to body temperature or incubation
in fresh human plasma (Fig. 1B). After 30 min incubation at 37 °C, both
HSPC and DSPE liposomes maintained almost complete encapsulation
of their payload (Fig. 1B), with no more than 5% of the input dose
being detected as free agent at any time point. In mice engineered to
have endogenous expression of luciferase in all tissues, the injection of
free luciferin produced luminescent signal throughout (Fig. 1C). In con-
trast, when the same amount of luciferin was delivered encapsulated
within either ‘Doxil’-like HSPC or our DSPE liposomes negligible lumines-
cence was detected, demonstrating that these two formulations achieved
equivalent stability during this 30-min time frame. Indeed, the bladder of
micewas the only sitewhere any luciferin signalwas detected, suggesting
release was not achieved until the degradation and excretion of the lipo-
some constructs. In subsequent pre-clinical studies of cavitation-triggered
payload release from DSPE liposomes, the measurement of tumor lumi-
nescence was taken 30 min after intravenous injection.
3.2. In vitro analysis of sensitivity to ultrasound-induced inertial cavitation
events
In vitro testing of the cavitation-induced release of payload from
liposomes was performed using a 0.5-MHz transducer focused on a
6.3-cm3 cylindrical phantom containing degassed phosphate-buffered
saline (PBS) with or without liposome test sample and with or withoutSonoVue® (SV) (seemethods). The setup is demonstrated diagrammat-
ically in Supplementary Fig. 1. TheUS exposure conditionswere tailored
to the eventual studies in murinemodels by giving consideration to the
parameters that are achievable and necessary in vivo. Notably, the pulse
repetition frequency (PRF) was designed to mimic the need for replen-
ishment of SV cavitation nuclei into the focus of the transducer in a ﬂow
scenario such as the vessels within a tumor [26]. Exposure pressures
were varied to achieve a range of acoustic responses from low energy,
stable cavitation to high-energy inertial cavitation as characterised by
the power spectra of acoustic emissions [12,15].
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104 S.M. Graham et al. / Journal of Controlled Release 178 (2014) 101–107In the absence of SV, no acoustic emissionswere observed at any ex-
posure pressure, indicating that such pressures were insufﬁcient to in-
stigate the creation of gas bubbles in the test media (data not show).
In contrast, Fig. 2A shows that in the presence of SV acoustic emissions
could be detected and characterised across a range of exposure pres-
sures. At 0.14 MPa (panel i), low-energy spectra with ﬁxed frequencies
were detected and plotted as multiple horizontal lines on the power
spectral density plot (for example, at about 2.5 MHz, see red arrow).
Such repeated signal at the same frequency is indicative of stable cavita-
tion taking place with bubbles oscillating to produce harmonics of the
0.5-MHz driving frequency. The energy of emissions increased as expo-
sure pressure increased to 0.5 MPa or 0.8 MPa (panel ii and iii). In addi-
tion to harmonic emissions, a pattern of vertical lines (black arrows)
was observed showing that for each US exposure an acoustic response
comprised of a wide range of frequencies (2.5 MHz–10 MHz) was also
detected. Such broadband emissions are characteristic of the shock
waves created when unstable bubble oscillation leads to inertial cavita-
tion. These emissions persist throughout the 30-s exposure, indicating
that the amount of viable SV is not exhausted within this timeframe.
At 1.2 MPa or 1.5 MPa (panels iv and v), high-energy broadband emis-
sions dominated the signal as seen previously [15]; however, there is a
decay in the signal at the end of the 30 s. This is due to the more rapid
destruction of SV bubbles at these pressures, as also evidenced by a
decrease in the opacity within the phantom during exposure. The
presence of liposomes did not inﬂuence the spectra produced with
SonoVue present, and liposomes alone showed no cavitation signals
on the power spectra (Supplementary Fig. 2B). When HSPC liposomes
were tested in the absence of SV, the application of pressures from
0.14 MPa up to 1.5 MPa failed to trigger the release of payload
(Fig. 2B). When SV was included, regardless of the acoustic emissions
detected, i.e., low-energy stable cavitation at 0.14 MPa or high-energy
inertial cavitation at 1.5 MPa, there was still no enhancement in the re-
lease of luciferin payload. This indicates that under these exposure
conditions these control HSPC ‘Doxil’-like formulation did not give the
triggered release of its payload.
Notably, thermocouple measurements demonstrated that no in-
crease in temperature was detected within the phantom at any of the
exposure conditions tested (Supplementary Fig. 3A). Furthermore,
stability tests performed by heating DSPE sample to 43 °C showed no
increase in luciferin payload release (Supplementary Fig. 3B).
When DSPE liposomes were reformulated to contain doxorubicin
rather than luciferin, the release of this drug could be triggered using
the same inertial cavitation, instigating conditions (Supplementary
Fig. 4A) that provided triggered release in Fig. 2C. Speciﬁcally, only
PRFP values of 1.2 MPa or 1.5 MPa gave substantial and signiﬁcant
(p b 0.05) increases in release and this was only in the presence of
SonoVue. This ultimately led to enhanced kill when these samples
were added to B16-F10-luc cancer cells in vitro (Supplementary
Fig. 4B). Indeed, the level of cell kill was equivalent to that achieved
with the same amount of free drug and 2-fold higher than that achieved
with samples where no enhanced doxorubicin release was detected.
Similarly, when DSPE liposomes were tested in the absence of SV, no
release of luciferin payload was observed following exposure to
pressures ranging from 0.14 MPa to 1.5 MPa. Upon the inclusion of SV,
the application of 0.14 MPa, 0.5 MPa or 0.8 MPa and the associatedFig. 2. In vitro assessment of inertial cavitation induced drug release. The 0.5-MHz ultra-
sound was used to expose samples at 5% duty cycle with 50,000 cycle pulses with a pulse
repetition frequency of 0.5 Hz for 30 s. (A) Representative power spectral densities of
DSPE liposomes in the presence of SV at (i) 0.14 MPa, (ii) 0.5 MPa, (iii) 0.8 MPa, (iv)
1.2 MPa and (v) 1.5 MPa. Drug release from HSPC liposomes (B) and DSPE liposomes (C)
is shown as percentage increase from background (non-exposed) samples over the pres-
sure range tested. Two-way ANOVA for signiﬁcance, ***p b 0.001, n = 3, standard devia-
tion shown. (D) Correlation between energy of acoustic emissions and liposomal release
is shown for each sample set of HSPC liposomes and DSPE liposomes in the absence and
presence of SV. n = 3, standard deviation for both energy and release is shown.
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that resulted did not cause luciferin release. However, when a pressure
of 1.2 MPa or 1.5 MPa was applied and high-energy inertial cavitation
was instigated, broadband energy dominated the power spectrum and
signiﬁcant release of luciferin (30%, p b 0.001, ANOVA) payload from
the liposomes was observed (Fig. 2C). It is important to emphasise that
this triggered release was not instigated by US exposure per se but by
speciﬁc inertial cavitation events. It is notable that such events can be
tightly regulated and monitored using the systems described here. This
adds to the potential clinical utility of the approach we have described.
The energy of acoustic emissions associated with the chaotic bubble
oscillation increased almost linearly with applied ultrasound pressure
(Supplementary Fig. 2). A correlation between percentage release and
electrical energy from acoustic emissions can be seen in Fig. 2D, where
below 1.68 μJ no signiﬁcant release is seen from either HSPC liposomes
or DSPE liposomes. Above 1.68 μJ, an increase in release fromDSPE lipo-
somes is seen whereas HSPC liposomes remain stable.
3.3. In vivo analysis of focused ultrasound mediated payload release
Having established the beneﬁt of using DSPE rather than HSPC
liposomes and identiﬁed the US parameters capable of producing opti-
mal triggered release, experiments were performed in a murine pre-
clinical model using the setup represented by Bazan-Peregrino et al.
[24]. The circulation kinetics and organ distribution of DSPE liposomes
loaded with luciferin were tested in C57Bl6 mice bearing B16F10-
luciferase tumors. Inertial cavitation taking place within the focal
volume was detected in real-time throughout the 12-min exposure
(representative trace shown in Fig. 3A). Multiple re-dosing with SV (at
each red arrow) was required to provide a constantly replenished
source of cavitation nuclei [27], whilst repositioning of the US focal vol-
ume (blue arrows) ensured the maximum possible volume of tumor
was exposed.Notably, distinct cavitation eventswere detected upon ad-
ministration of SV, but the magnitude of the events was dramatically
different at different sites within the same tumor. This emphasises the
substantial inter-regional differences in perfusion and, therefore, SV
content throughout the tumor [28] and highlights the importance of
achieving good US exposure over the whole tumor volume. It is also
noteworthy that the exposure parameters used in these studies caused
no damage to the skin of the mice, in contrast to studies that have used
higher pressures [29], emphasising the improved safety proﬁle of our
approach.
Pharmacokinetic and biodistribution studies (Figs. 3B and 3C) dem-
onstrated that there was no signiﬁcant change in liposomal clearance
proﬁle or tumor accumulation in mice treated with liposomes +
SV + US compared to those treated with only liposomes + SV. In
both cases, approximately 75% of the injected dose was present in
the circulation at 30 min and just 1% was present in tumors. These
ﬁgures are a measure of sum total of free and encapsulated luciferin
present. However, the combination of US + SV did provide a sub-
stantial and signiﬁcant increase in the level of luciferin released
within tumors. When imaged directly after treatment a 16-fold
(p b 0.001) increase in photons/second/cm2 was detected in theFig. 3. Assessment of the pharmacokinetics, biodistribution and drug release proﬁle of
DSPE liposomes in vivo. C57BL6mice bearing B16F10-luciferase tumorwere intravenously
dosed and bloods collected, US exposures performed and organs imaged and harvested
and described in methods. (A) Representative normalised variance (blue line) calculated
from the acoustic emissions detected by the passive cavitation detector over the 12-min
US exposure regime; red arrows denote times of SV administration, and blue arrows de-
note the repositioning of US focal volume with respect to tumor volume. (B) Clearance
proﬁle of liposomes from the blood of mice with US-treated (red diamond) and non-US-
treated (black diamond, dashed line) tumors. (C) Tumor and liver accumulation of lipo-
somes in mice with US-treated (red bar) or non-US-treated (black bar) tumors shown
as a percentage of the injected dose. (D) IVIS imaging of luminescence in mice and
mean levels plotted for US-treated (red bar) or non-US-treated (black bar) tumors. In all
experiments, n = 3, standard deviation shown, Student's t-test for signiﬁcance,
***p b 0.001.
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which received liposomes + SV alone, demonstrating a substantial
and signiﬁcant enhancement of the delivery of luciferin to the lucif-
erase expressing tumor cells (Fig. 3D).
4. Discussion
Ultrasound (US) is emerging as a powerful therapeutic modality
[30,31], particularly in the context of improving the delivery of liposo-
mal drug carriers to target tumors [32]. Strategies are now being devel-
oped so that the release of payload from liposomes can also be triggered
using US. In accordance with recent publications, we have demonstrat-
ed that US can be used as a trigger to disrupt blood-stable liposome for-
mulations and cause such drug release [11,14]. Our in vitro studies
demonstrate that release is dependent on liposome composition, with
Doxil-like phosphocholine liposomes proving non-US-responsive,
whereas phosphoethanolamine liposomeswith the same heat and plas-
ma stability showed up to 30% release upon US exposure. This may be a
consequence of reported differences in packing parameter and the con-
sequent propensity of phosphoethanolamine lipids to destabilise and
form inverted hexagonal structures [33,11]. The analysis of the acoustic
emissions resulting from US exposure enabled us to prove that inertial
cavitation, as characterised by broadband emissions [15], was the phe-
nomenon required to drive this payload release. The co-delivery of SV
provided the nuclei for the initiation of such phenomenon and in its ab-
sence no inertial cavitation or drug release was observed. The presence
of SV allows inertial cavitation events to be created at exposure frequen-
cies and pressures that are within the range of current diagnostic US
scanners. Themechanical index (MI) used in diagnostic imaging usually
ranges from 0.04 to 1.7 [34]. Even though theMI is not directly applica-
ble for ultrasound pulses longer than a single cycle, the lowest pressure
where release was seen (1.2 MPa) would have a corresponding MI of
1.697. By co-injecting SonoVue, we were able to trigger payload release
at a spatial peak average pulse intensity (ISPPA) of 0.0486 kW/cm2
compared to the reported 10.5 kW/cm2 required to achieve cavitation
and payload release without pre-existing bubbles [14]. These factors
combine to enhance the safety and clinical applicability of the approach
we have taken. However, it is notable that at the highest pressure of ex-
posure 1.5 MPa, there was a loss in both the proportionality of the total
energy produced by acoustic emissions over the exposure period
and the amount of payload release achieved. This meant that
1.5 MPa exposure gave no signiﬁcant increase in either of these
facets compared to the use of 1.2 MPa, which is probably the result
of the exhaustion of the supply of SV inertial cavitation nuclei within
the 30-s exposure. This serves to emphasise the importance of
maintaining a constant supply of cavitation nuclei throughout the
US exposure. This factor was considered when designing the pulse
repetition frequency of our US pulses to align with what was achiev-
able and useful in vivo [26].
Our in vivo studies were performed by intravenous injection of iner-
tial cavitation sensitive DPSE liposomes into a murine model. Delivery
and acoustic parameters were optimised to achieve a constant supply
of SV and insonation of a large tumor area. Notably, dramatic differences
in acoustic response were observed in different regions of the tumor.
This serves to both emphasise the importance of good tumor perfusion
in order to allow a constant supply of SV and highlight the value of being
able to obtain real-time feedback on the occurrence of inertial cavitation
as delivery is taking place. Inertial cavitation was shown to be a neces-
sary requirement for luciferin release from liposomes. The detection of
inertial cavitation can therefore be used as a non-invasive, reliable and
accurate proxy for themeasurement of the release of payload from lipo-
somes. This has important beneﬁcial ramiﬁcations for the clinical utility
of this ultrasound technology, potentially providing clinicianswith low-
cost, real-time, non-invasive feedback on the success of drug delivery,
something which no other imaging modality can currently provide.
Such measurement of the acoustic output from cavitation events andits correlation with drug release offers substantial beneﬁt over the ap-
proach of using acoustic input as a proxy for release [35] because of
the stochastic nature of the creation of inertial cavitation events, espe-
cially in complex biological environments. However, the variability in
the levels of inertial cavitation we observe between different tumor re-
gions highlights a weakness of our approach in that the SV delivered to
provide cavitation nuclei may not achieve sufﬁcient and liposome-
coincident intratumoral distribution. This is due to the uniquely
deregulated state of the vascularisation foundwithin tumors [36]. A fur-
ther limitation of our approach is the requirement to replenish SV be-
cause it is destroyed in the act of generating cavitation events. To
address these limitations, particles designed to provide more sustain-
able and reliable cavitation nuclei will need to be developed.
The fact that SV delivery provided variable intratumoral inertial cav-
itation levels may explain why nomeasurable diminishment in the cir-
culating liposome dose or increase in total luciferin level within tumors
was observed. Indeed, this is in accordancewith similar studieswe have
performed using SVwith oncolytic virus. However, it contrasts marked-
ly with our studies using high intensity focused ultrasound to instigate
heat mediated liposome destabilisation, where complete drug release
can be achieved [37]. In our studies, triggered release from cavitation
sensitive DSPE formulations is still sub-optimal and some way behind
the release achieved from heat-sensitive formulations [9].
However, despite the variability in intratumoral inertial cavitation
levels and location, sufﬁcient events were generated to instigate sub-
stantial and highly signiﬁcant increases in payload release. This demon-
strates that although increases in the total amount of luciferin reaching
the tumor could not be achieved, US + SV did instigate an increase in
the amount of luciferin released, thereby providing an 16-fold increase
in the bio-available dose within the tumor. This is the ﬁrst demonstra-
tion that such clinically applicable US parameters can be used to im-
prove intratumoral payload release from an intravenously injected
liposomal delivery agent.
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